- x
- Mr.Leonard Chang
ROSUVASTATIN CAS NO.147098-20-2
- FOB Price: USD: 1.00-1.00 /Metric Ton Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: L/C,T/T
- Available Specifications:
1(1-2)Metric Ton1(1-2)Metric Ton
- Product Details
Keywords
- rosuvastatin calcium
- atorvastatin calcium
- 147098-20-2
Quick Details
- ProName: ROSUVASTATIN
- CasNo: 147098-20-2
- Molecular Formula: C44H54CaF2N6O12S2
- Appearance: powder
- Application: cardiovascular disease
- DeliveryTime: promptly
- PackAge: 5-25 kg per drum
- Port: shanghai
- ProductionCapacity: 1 Kilogram/Day
- Purity: 1
- Storage: dry price
- Transportation: cif air
- LimitNum: 10 Gram
- Related Substances: 1
- Residue on Ignition: 1
- Heavy Metal: 1
- Valid Period: 1
Superiority
EDMF, EUGMP, high quality,
Details
EDMF, EUGMP, high quality,
Rosuvastatin (marketed by AstraZeneca as Crestor, Abbott Laboratories as R2) is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. Crestor is the fifth-highest selling drug in the United States, accounting for approx. $2.6 billion in sales in 2013 .
Rosuvastatin is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia), and/or triglycerides (hypertriglyceridemia).[11] In February 2010, rosuvastatin was approved by the FDA for the primary prevention of cardiovascular events.[12]
As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.[13]
The results of the JUPITER trial (2008) suggested rosuvastatin may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia, but with elevated levels of highly sensitive C-reactive protein. This could strongly impact medical practice by placing many patients on statin prophylaxis who otherwise would have been untreated.[14][15] As a result of this clinical trial, the FDA approved rosuvastatin for the primary prevention of cardiovascular events.[12]
The AURORA trial randomized 2776 patients undergoing hemodialysis due to kidney damage to receive either rosuvastatin or placebo. The randomized, double-blind study (2005 to 2009) found no difference in the two groups in the primary end-point, a combination of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The study found no difference in all-cause mortality among this population at a mean follow-up of 3.8 years